NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

NEW YORK, Oct. 17, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Elanco Animal Health Incorporated (NYSE: ELAN). Shareholders who purchased shares of ELAN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/elanco-animal-health-incorporated-loss-submission-form/? id=108706&fro ...

NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Elanco Animal Health Incorporated (NYSE: ELAN). Shareholders who purchased shares of ELAN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/elanco-animal-health-incorporated-loss-submission-form/? id=108477 ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Elanco To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Elanco between November 7, 2023 and June 26, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 16, 2024 (GLOBE NEW ...

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

NEW YORK, Oct. 15, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Elanco Animal Health Incorporated ("Elanco" or the "Company") (NYSE: ELAN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Elanco investors who were adversely affected by alleged securities fraud between November 7, 2023 and June 26, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/elanco-animal-healt ...

Core Viewpoint - A class action lawsuit has been filed against Elanco Animal Health Incorporated for failing to disclose issues related to the approval of its drugs, specifically Zenrelia and Credelio Quattro, during the class period from November 7, 2023, to June 26, 2024 [1][2]. Group 1: Allegations and Company Developments - The lawsuit alleges that Elanco did not disclose that Zenrelia was less safe than previously indicated and that the company was unlikely to meet its own timelines for FDA approval and commercial launch of Zenrelia and Credelio Quattro [4]. - Elanco's press release on June 27, 2024, revealed that Zenrelia would likely include a boxed warning on safety, which could slow product adoption by approximately 25% [3]. - The expected timeline for FDA approval was pushed to the third quarter of 2024 for Zenrelia and the fourth quarter of 2024 for Credelio Quattro, leading to a significant drop in Elanco's stock price by $3.69 per share, or 20.53%, closing at $14.28 per share [3]. Group 2: Legal Proceedings and Shareholder Information - Shareholders interested in participating in the class action must submit their application to serve as lead plaintiff by December 6, 2024 [5]. - The law firm Robbins LLP, which is handling the case, operates on a contingency fee basis, meaning shareholders will not incur fees or expenses unless the case is successful [6].

NEW YORK, Oct. 14, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Elanco Animal Health Incorporated (NYSE: ELAN). Shareholders who purchased shares of ELAN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/elanco-animal-health-incorporated-loss-submission-form/? id=107864&fro ...

Core Viewpoint - A securities fraud class action has been filed against Elanco Animal Health Incorporated, alleging that the company made materially false and misleading statements regarding its business and product safety during the class period from November 7, 2023, to June 26, 2024 [1][3]. Company Overview - Elanco Animal Health Incorporated is based in Greenfield, Indiana, and specializes in the development and manufacture of pharmaceuticals and vaccines for pets and livestock [3]. Securities Fraud Claims - The complaint alleges that Elanco's management failed to disclose critical information, including: - Zenrelia was less safe than previously communicated to investors [3]. - The company was unlikely to meet its timeline for U.S. approval and commercial launch of Zenrelia and Credelio Quattro [3]. - Consequently, Elanco's business and financial prospects were overstated [3]. Impact of Recent Announcements - On June 27, 2024, Elanco announced that Zenrelia's U.S. label would include a safety warning, which is expected to slow product adoption and limit treatment days by approximately 25% [4]. - Following this announcement, Elanco's stock price fell by $3.69 per share, or 20.53%, closing at $14.28 on the same day [4].

NEW YORK, Oct. 13, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Elanco Animal Health Incorporated (NYSE: ELAN) between November 7, 2023 and June 26, 2024, both dates inclusive (the "Class Period"). A class action has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 6, 2024. SO WHAT: If you purchased Elanco Animal Health Incorpor ...